Rethinking modRNA Immunogenicity: Toward a Human Genotype-Guided PRR/ISR Atlas
Preprint
- 9 May 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
In vitro-transcribed modified mRNA is a promising platform for transient protein replacement in regenerative medicine, including cardiomyocyte regeneration, but repeated dosing is limited by variable innate immune activation and ISR-mediated translation shutdown across individuals. We propose a Human-specific PRR/ISR Immunogenicity Atlas: a focused, genotype-aware computational framework linking patient genetic variation in pattern recognition receptors and ISR components to predict immune and translation responses for IVT modRNA. The Atlas generates individualized “genetic passports” that stratify responder risk, estimate cytokine and PKR/eIF2α activation, and prioritize clinically feasible temporary knockdown strategies (LNP-siRNA/ASO or small molecules). We outline a six-stage roadmap covering data integration, feature engineering, multi-modal modeling, uncertainty quantification, a knockdown prioritization module, and open deployment. Ethical, privacy, ancestry-representation, and regulatory considerations are discussed, along with a staged validation strategy. This Atlas provides a conceptual and practical framework to support safer, more consistent protein replacement in regenerative medicine by moving from one-size-fits-all to genotype-guided approaches.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025Vaccine, 2025
- The strategies and advances of mRNA translation boosterAsian Journal of Pharmaceutical Sciences, 2025
- mRNA-based technology for engineered regenerative medicineCell Biomaterials, 2025
- Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNAMolecular Therapy Nucleic Acids, 2025
- Human immune system: Exploring diversity across individuals and populationsHeliyon, 2025
- SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress responseVirus Research, 2023
- Therapeutic siRNA: State-of-the-Art and Future PerspectivesBioDrugs, 2022
- Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message acrossAdvanced Drug Delivery Reviews, 2021
- Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) AmyloidosisThe Journal of Clinical Pharmacology, 2019
- Evading innate immunity in nonviral mRNA delivery: don’t shoot the messengerDrug Discovery Today, 2016